Aarti Pharmalabs share news and announcements
NSE: AARTIPHARMBSE: 543748Pharmaceuticals & BiotechnologySmall Cap
Last close ₹820.85down ₹7.95 (0.96%)BSE ₹821.05
Share price at the NSE close on 23 Oct 2026. Previous close ₹828.80.
52-week range of traded prices to 23 Oct 2026
₹585.00Low, 30 Mar 2026₹1,002.40High, 30 Sep 2026
- Next results date: the board meets on 28 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹7,443 Cr705th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 25 May 2026
- 3.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.43%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 25 May 2026
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,02,86043.1% delivered
Aarti Pharmalabs share news and announcements
154 announcements, routine notices left out, newest first. Page 3 of 4.
Aug 2024
5 Aug · Board meeting
Jul 2024
29 Jul · Analysts
15 Jul · Corporate action
14 Jul · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited with respect to announcement dated 13-May-2024, regarding Appointment of Mrs Nehal Garewal as Non- Executive Director of the company w.e.f. May 13, 2024.". On basis of above the Company is required to clarify following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.
Jun 2024
26 Jun · Rating
10 Jun · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
May 2024
13 May · Management
13 May · Disclosure
4 May · Analysts
Feb 2024
7 Feb · Corporate action
1 Feb · Analysts
Jan 2024
4 Jan · Disclosure
Dec 2023
Nov 2023
4 Nov · Analysts
Oct 2023
Sep 2023
Aug 2023
7 Aug · Analysts
Jul 2023
May 2023
23 May · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.15 May · Related Party Transactions
12 May · Related Party Transactions
12 May · Management
12 May · Board meeting